title: Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C.
authors.forename: Claudia
authors.initials: C
authors.lastname: Colomba
authors.forename: Raffaella
authors.initials: R
authors.lastname: Rubino
authors.forename: Lucia
authors.initials: L
authors.lastname: Siracusa
authors.forename: Giovanni
authors.initials: G
authors.lastname: Mazzola
authors.forename: Lucina
authors.initials: L
authors.lastname: Titone
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D017576:Daptomycin / Q000008:administration & dosage / Q000009:adverse effects*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000473:pathology; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000900:Anti-Bacterial Agents; D000998:Antiviral Agents; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; D017576:Daptomycin